Viatris' corporate branding was unveiled by Tianxiang Miao, Chairman and President of Pfizer-Principal Greater China and future Chairman of Viatris Greater China, who said at the unveiling ceremony that Viatris has 45,000 employees worldwide with expertise in science, manufacturing, quality, registration and medical affairs, and serves patients in more than 165 countries and territories. services.
Pfizer Preqen was originally Pfizer's patent-expiring brands and generics business unit, and Mylan is a global pharmaceutical company.On July 29, 2019, Mylan and Pfizer announced a definitive agreement to merge Mylan with Pfizer's patent-expiring brands and generics business unit, Preqen, in order to create a new global pharmaceutical company.
Under the terms of the agreement, which is structured as an all-stock, reverse Morris Trust transaction, each share of McLane stock will be converted into one share of stock in the new company. Pfizer shareholders will own 57 percent of the new combined company, while McLane shareholders will own 43 percent. The boards of directors of McLane and Pfizer have unanimously approved the deal.
On July 31 of this year, Milan and Pfizer unveiled the brand identity and connotations of the combined company, VIATRIS, which is said to be derived from the Latin term for "three great pathways," and which visually embodies the company's commitment to accessibility, leadership and collaboration. The Three Ways harmonize around the Earth icon to reflect the company's core purpose of helping people around the world live healthier lives at every stage of life.
The combined company has a diverse global product portfolio of approximately 1,400 compounds and biologics. In China, the company currently has a portfolio of more than 20 medicines covering a wide range of therapeutic areas, including cardiovascular, mental health, urology, pain, hepatology and infections, orthopedics and rheumatology, and allergies.
Lipitor and Lovoxil, the iconic cardiovascular products from Phuong, have been on the market in China for more than 20 years, benefiting tens of millions of patients; Viagra, the star product in the field of men's health, has also been on the market for 20 years and has brought good news to many families.
Mayland's many products have a good reputation in the Chinese market, including Sulbivolol, Ainonda, Viguardia, and Rigalon. In the field of liver disease and infection, in addition to the products already marketed in China, Mylan has a rich product portfolio and pipeline globally. In addition, Mylan is a global leader in HIV treatment, with a number of novel anti-AIDS drugs on sale or in development.
Ni Xiangyang, senior vice president of global strategy, business development and commercial capabilities at Pfizer Phuong, and future president of Fai Chi Greater China, said Fai Chi combines Phuong's trusted, iconic brands with Milan's broad and diverse portfolio of products across all major therapeutic areas.
As for Fai Chi's recent new drug launches and future plans, Ni Xiangyang said the French-imported Viagra orally disintegrating tablets have already been launched in China this October
.